OmniFusion™ RNA Lung Cancer Panel known and novel fusion detection and research via amplicon-based target enrichment for Next Generation Sequencing (NGS) on Illumina sequencing platforms
OmniFusion RNA Lung Cancer Panel for next generation sequencing enables detection more than 530 known and unknown fusions associated with non-small cell lung cancer. In contrast to the AccuFusion™ panels, OmniFusion workflow allows detection of novel fusion partners and and splicing variants. Compared to other methods such as qPCR, FISH, or Sanger sequencing, Paragon Genomics targeted fusion sequencing method allows robust multiplexed detection of variants using minimum sample input and a simple workflow (Figure 1).
The OmniFusion single-primer amplification technology uses template switching technology to add an universal sequence to the 5’ ends of RNA fragments. Combined with expertly designed targeted 3’ primers specific to acceptor genes, the process eliminates the constraint of template length, and allows higher sensitivity even with damaged RNA fragments, such as FFPE RNA. The single sided amplification method enables the detection of any mutations on the RNA fragments, including novel ones.
Learn more about the technology on our Fusion Technology page.
- Identification of known and novel RNA fusions associated with lung cancer
Interrogate >530 known RNA fusion and additional novel RNA fusion using a single-primer method.
- Fast, streamlined workflow
Generate sequencing-ready libraries in just 6.5 hours using a rapid, five-step protocol from Extracted RNA to sequence ready libraries.
- Excellent performance with extremely low rRNA rate
Prepare high-quality targeted NGS libraries using OmniFusion RNA Fusion Detection Technology to achieve minimal rRNA and over 90% on-target rate.
- Sensitive Detection
Can detect down to 1% variant frequency with high confidence.
Store at -20 °C.
For Research Use Only. Not for use in diagnostic procedures.